Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Solid Biosciences Receives FDA IND And Health Canada CTA Approval For First-In-Class Cardiac Gene Therapy To Treat Catecholaminergic Polymorphic Ventricular Tachycardia

Author: Benzinga Newsdesk | July 08, 2025 03:08pm

- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies -

- SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA -

- Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 -

- Expands Solid's clinical pipeline to include first cardiac indication with urgent unmet medical need -

Posted In: SLDB